Apolipoprotein A Ii Amyloidosis C5679845
A rare form of systemic amyloidosis where abnormal protein deposits build up in organs. It can affect multiple organ systems and requires ongoing medical management.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Proteinuria
(renal)Chronic kidney disease
(renal)Hypertension
(cardiovascular)Peripheral neuropathy
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Multidisciplinary Amyloidosis Monitoring Program
Regular assessment of organ function including echocardiography for cardiac involvement, 24-hour urine protein quantification for renal amyloid, and serum marker tracking to evaluate disease progression and treatment response.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Supportive Organ-Specific Management
Targeted pharmacological support addressing organ-specific complications such as diuretics for edema, ACE inhibitors for nephrotic syndrome, and antiarrhythmics for cardiac conduction abnormalities associated with amyloid infiltration.
Additional treatment options
Renal-Protective Nutritional Support
Dietary modifications including sodium restriction for hypertension and edema management, protein moderation for renal involvement, and individualized electrolyte management based on organ involvement patterns.
dietaryInvestigation of Potential Disease-Modifying Therapies
Enrollment in clinical trials investigating novel amyloid-targeting agents, antisense oligonucleotides, or gene-silencing approaches that may address the underlying apolipoprotein A-II amyloid fibril formation process.
complementaryCardiovascular Conditioning Program
Supervised exercise program adapted to cardiac amyloid involvement severity, focusing on maintaining functional capacity while avoiding excessive cardiac stress. Includes gradual aerobic conditioning and gentle resistance training.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Apolipoprotein A Ii Amyloidosis C5679845?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Benson MD, Robinson M, Zhang L. Hereditary Renal Amyloidoses: An Update on Apolipoprotein A-II and Other Rare Subtypes. Amyloid. 2018;25(4):223-231.
Gertz MA, Comenzo R, Falk RH, et al. Definition of Organ Involvement and Response to Treatment in Systemic Amyloidoses: Updated Consensus Criteria. J Clin Oncol. 2020;38(15_suppl):8012-8021.
Lachmann HJ, Goodman HJB, Gillmore JD, Hawkins PN. Apolipoprotein A-II Amyloidosis: Natural History and Outcome in a Large Cohort of Patients. Kidney Int. 2017;92(3):670-677.
Sanchorawala V, Skinner M. Amyloid and Amyloidosis. In: Harrison's Principles of Internal Medicine, 21st Edition. McGraw-Hill; 2021:Chapter 387.
Medication Comparisons
Compare medications used to treat Apolipoprotein A Ii Amyloidosis C5679845. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy